These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25792221)

  • 21. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly.
    Neggers SJ; van Aken MO; Janssen JA; Feelders RA; de Herder WW; van der Lely AJ
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4598-601. PubMed ID: 17895318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.
    Feenstra J; van Aken MO; de Herder WW; Feelders RA; van der Lely AJ
    Eur J Endocrinol; 2006 Jun; 154(6):805-6. PubMed ID: 16728538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigational therapies for acromegaly.
    Grasso LF; Pivonello R; Colao A
    Expert Opin Investig Drugs; 2013 Aug; 22(8):955-63. PubMed ID: 23731031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The place of pegvisomant in the acromegaly treatment algorithm.
    Paisley AN; Trainer PJ; Drake WM
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S101-6. PubMed ID: 15135788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lessons from 6 years of GH receptor antagonist therapy for acromegaly.
    Trainer PJ
    J Endocrinol Invest; 2003; 26(10 Suppl):44-52. PubMed ID: 15497659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medical Treatments for Acromegaly: A Systematic Review and Network Meta-Analysis.
    Leonart LP; Ferreira VL; Tonin FS; Fernandez-Llimos F; Pontarolo R
    Value Health; 2018 Jul; 21(7):874-880. PubMed ID: 30005760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New perspectives in the medical treatment of acromegaly.
    Colao A; Pivonello R; Auriemma RS; Galdiero M; Guerra E; Milone F; De Leo M; Lombardi G
    J Endocrinol Invest; 2005; 28(11 Suppl International):58-66. PubMed ID: 16625847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegvisomant: current and potential novel therapeutic applications.
    Thankamony GN; Dunger DB; Acerini CL
    Expert Opin Biol Ther; 2009 Dec; 9(12):1553-63. PubMed ID: 19916734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of efficacy and tolerability of somatostatin analogs and other therapies for acromegaly.
    Burt MG; Ho KK
    Endocrine; 2003 Apr; 20(3):299-305. PubMed ID: 12721511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of endocrine disease: GH excess: diagnosis and medical therapy.
    Andersen M
    Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study.
    Chiloiro S; Bima C; Tartaglione T; Giampietro A; Gessi M; Lauretti L; Anile C; Colosimo C; Rindi G; Pontecorvi A; De Marinis L; Bianchi A
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5478-5482. PubMed ID: 31219586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials.
    Jimenez C; Burman P; Abs R; Clemmons DR; Drake WM; Hutson KR; Messig M; Thorner MO; Trainer PJ; Gagel RF
    Eur J Endocrinol; 2008 Nov; 159(5):517-23. PubMed ID: 18708436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
    Marazuela M; Lucas T; Alvarez-Escolá C; Puig-Domingo M; de la Torre NG; de Miguel-Novoa P; Duran-Hervada A; Manzanares R; Luque-Ramírez M; Halperin I; Casanueva FF; Bernabeu I
    Eur J Endocrinol; 2009 Apr; 160(4):535-42. PubMed ID: 19147599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant.
    Strasburger CJ; Mattsson A; Wilton P; Aydin F; Hey-Hadavi J; Biller BMK
    Eur J Endocrinol; 2018 Apr; 178(4):321-329. PubMed ID: 29371335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New formulations and approaches in the medical treatment of acromegaly.
    Debono M; Newell-Price J
    Curr Opin Endocrinol Diabetes Obes; 2010 Aug; 17(4):350-5. PubMed ID: 20502324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Optimization of the medical treatment for acromegaly].
    Díez JJ; Iglesias P
    Med Clin (Barc); 2013 Apr; 140(8):360-5. PubMed ID: 23103101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipodystrophy in patients with acromegaly receiving pegvisomant.
    Bonert VS; Kennedy L; Petersenn S; Barkan A; Carmichael J; Melmed S
    J Clin Endocrinol Metab; 2008 Sep; 93(9):3515-8. PubMed ID: 18611977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.
    Ciresi A; Radellini S; Guarnotta V; Giordano C
    BMC Endocr Disord; 2018 Jan; 18(1):2. PubMed ID: 29361932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Growth hormone receptor antagonist in the treatment of acromegaly].
    Hubina E; Tóth A; Kovács GL; Dénes J; Kovács L; Góth M
    Orv Hetil; 2011 May; 152(18):709-14. PubMed ID: 21498159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial.
    Madsen M; Krusenstjerna-Hafstrøm T; Møller L; Christensen B; Vendelbo MH; Pedersen SB; Frystyk J; Jessen N; Hansen TK; Stødkilde-Jørgensen H; Flyvbjerg A; Jørgensen JO
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1227-35. PubMed ID: 22298804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.